### Edgar Filing: KAKKIS EMIL D - Form 4

KAKKIS El Form 4 March 04 2										
Check this box Check this box									3235-0287 January 31, 2005 verage	
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> KAKKIS EMIL D			Issuer Name <b>ai</b> ibol DMARIN PH C [BMRN]			8	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE							Director 10% Owner X Officer (give title Other (specify below) below) Chief Medical Officer			
NOULTO	(Street)		Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
NOVATO,							Person		porting	
(City)	(State)	(Zip)	Table I - Non	-Derivativ	e Secu	rities Acqu	iired, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Code ear) (Instr. 8)	TransactionDisposed of (D)Code(Instr. 3, 4 and 5)				6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	03/02/2009(1)	03/02/2009	М	7,897	А	\$ 6.43	47,518	D		
Common Stock	03/02/2009 <u>(1)</u>	03/02/2009	S	7,897	D	\$ 11.7001 (2)	39,621	D		
Common Stock							4,654	Ι	Shares held by spouse	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

#### Edgar Filing: KAKKIS EMIL D - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 6.43	03/02/2009	03/02/2009	М	7,897	01/06/2003 <u>(3)</u>	01/05/2013	Common Stock	7,897

## **Reporting Owners**

K

C 1 N S

Reporting Owner Name / Address		Relationships						
1	D	irector	10% Owner	Officer	Other			
CAKKIS EMIL D C/O BIOMARIN PHARMACEUTIO 05 DIGITAL DRIVE NOVATO, CA 94949	CAL INC.			Chief Medical Officer				
Signatures								
G. Eric Davis, httorney-In-Fact	03/04/2009							
**Signature of Reporting Person	Date							

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 Trading Plan executed March 1, 2008.
- The price in Column 4 is a weighted average price. The prices actually received ranged from \$11.66 to \$11.73. The reporting person will(2) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (3) Original option grant vested 1/48th on January 6, 2003 and 1/48th on the 6th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

#### **Reporting Owners**

### Edgar Filing: KAKKIS EMIL D - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.